Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1 1

Status

Completed 3Terminated 1

Sponsor Class

OTHER 4

Study Type

Interventional 4

Sponsor

Conditions

Myasthenia Gravis 4Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Leukemia, Lymphocytic, Chronic, B-Cell 1Common Variable Immunodeficiency 1Agammaglobulinemia 1

Interventions

Rituximab 7Pyridostigmine Bromide 5Prednisone 5efgartigimod alfa 4Hizentra 4telitacicept 3Immunoglobulins, Intravenous 3Cyclophosphamide 3Azathioprine 3thymoglobulin 2fludarabine 2Thymectomy 2Steroids 2Mycophenolic Acid 2Data Collection 2Blood Specimen Collection 2zilucoplan 1tofacitinib 1tocilizumab 1talquetamab 1sargramostim 1rozanolixizumab 1prednylidene 1gamma-Globulins 1deltacortene 1carmustine, poliferprosan 20 drug combination 1bu-zhong-yi-qi-tang 1apraclonidine 1Walk Test 1Therapeutics 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
OTHER × Myasthenia Gravis × Hizentra × Clear all
NCT04728425 2025-04-27

MG_SCIG

University Health Network, Toronto

Phase 2 Completed
30 enrolled

Myasthenia Gravis

NCT02774239 2023-02-21

SCIG-MG

University of Alberta

Phase 3 Completed
26 enrolled

Myasthenia Gravis

NCT02100969 2021-06-02

Open Label Study of Subcutaneous Immunoglobulin (SCIg) in Myasthenia Gravis

University of Kansas Medical Center

Phase 2 Completed
23 enrolled 18 charts

Myasthenia Gravis

NCT01828294 2019-04-03

SIMM

St. Louis University

Phase 1 Terminated
4 enrolled

Myasthenia Gravis

Data powered by HemOnc (CC BY 4.0) Colophon âš¡